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Editorial
Efficacy of lung cancer screening appears to increase with prolonged intervention: results from 
the MILD trial and a meta-analysis.
The long-term results of the Multicentric Italian Lung Detection (MILD) study [1] show a reduced 
lung cancer (LC) mortality at 10 years in the screened compared with the control arm (hazard ratio 
[HR] 0.61, 95% confidence interval [CI], 0.39-0.95); the HR for all-cause mortality was 0.80 (95% CI 
0.62-1.03). Screening benefits were more evident beyond the fifth year of screening, with HRs of 
0.42 (95% CI 0.22-0.79) for LC mortality and 0.68 (95% CI 0.49-0.94) for all-cause mortality.
These important findings add to our knowledge of LDCT screening efficacy. The National Lung 
Screening Trial (NLST) showed that screening with low-dose CT scan (LDCT) reduces LC mortality 
by 20% as compared to chest X-ray after a median follow-up of 6.5 years [2]. The results of the 
NLST were initially not replicated by smaller European trials [3-5], although preliminary results of 
the Dutch-Belgian Lung Cancer Screening Trial (NELSON) - the only European trial with adequate 
power - showed a reduction in LC mortality at 10 years [6]. While waiting for full publication of the 
NELSON trial, we carried out a systematic review and meta-analysis of the currently available 
evidence on LDCT screening for LC, including new results of the MILD [1] and preliminary results of 
the NELSON [6].
We performed a literature search in MEDLINE through PubMed and EMBASE from their 
inception date to 31 March 2019. Randomized controlled trials (RCTs) of lung cancer screening with 
LDCT as compared with other screening techniques were included. Both pilot and full RCTs were 
considered, without restrictions on publication type. Primary outcomes were LC mortality and all-
cause mortality at the longest follow-up available, at 5 years of follow-up, and beyond the fifth year 
of follow-up for studies reporting long-term results. Secondary outcomes were LC incidence, 
detection of LC at early stages (IA and IB) and detection of lung adenocarcinoma with LDCT.
A random-effects meta-analytic model [7] of between study variance was used to pool the 
estimates across studies. For LC mortality, all-cause mortality and LC incidence, we pooled together 
both HRs and relative risks (RRs) derived from the studies eligible for the meta-analysis. The 
estimates at 5 years of follow-up and those beyond the fifth year were extracted from the Kaplan-
Meier curves using the methods described by Tierney et al [8], or derived from the cumulative 
number of events and number of person-years at 5 years of follow-up or beyond. For detection of 
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2LC at early stages and detection of LC adenocarcinoma, the study-specific RRs were computed using 
as a denominator the total number of LCs detected within each study arms. 
A total of 460 records were retrieved from the literature search, of which 49 were assessed 
for eligibility by full-text reading. Three pilot RCTs [9-11] and 8 RCTs [1-6, 12, 13] were considered 
eligible, including a total of 51,426 subjects at high risk of LC randomized to LDCT and 50,322 to the 
control arm (Table 1). For the NLST trial [2] and its pilot study - the Lung Screening Study (LSS) [9] - 
subjects randomized to the control group underwent chest X-ray examination, while in the 
remaining studies [1, 3-6, 10-13] no screening was offered to subjects randomized to the control 
arm. The frequency (annual and/or biennial) and the number of LDCT examinations varied between 
studies, from three annual LDCT in NLST [2] to four annual in NELSON [6] and seven annual LDCT in 
MILD [1]. The DANTE study [3] included only men. The age of participants ranged between 45 to 75 
years. Median follow-up duration was 5.2 years in the LSS pilot study [9], 6.5 years in the NLST trial 
[2], 8.3 years in DANTE [3], nearly 10 years in ITALUNG [4] and DLCST [5] and above 10 years in MILD 
[1] and NELSON [6] studies. The German Lung Cancer Screening Intervention (LUSI) trial reported 
the results of the first 3 years of follow-up after randomization [12] and a Chinese community-based 
LC screening study only reported results of the baseline screening [13]. These studies were therefore 
not included in the meta-analysis.
Mortality results were reported from 8 studies [1-6, 12, 14]. The pooled estimates for LC 
mortality was 0.80 (95% CI, 0.71-0.90) (Figure 1). As also shown in MILD [1], reduction of LC mortality 
in the model estimate was greater beyond the fifth year of screening (RR 0.69, 95% CI 0.56-0.86). 
All-cause mortality was also reduced (RR 0.94, 95% CI 0.89-1.00), with a greater effect beyond the 
fifth year of screening (RR 0.82, 95% CI 0.71-0.95). Results for secondary outcomes showed that 
incidence of LC was higher in the LDCT arm (RR 1.69, 95% CI 1.30-2.19), and that LDCT screening 
allowinf fothr more frequent detection of LC cases at early stages IA and IB (RR 2.07, 95% CI 1.50-
2.85), as well as adenocarcinomas (RR 1.20, 95% CI 1.03-1.38).
Thus, the evidence on the efficacy of LDCT as screening for lung cancer in high-risk individuals 
that accumulated after the publication of the NLST in 2011 [2] largely confirms the results of that 
landmark trial. The prolonged follow-up of the MILD, including its landmark analysis showing a HR 
of 0.42 beyond the fifth year of screening, provides the most convincing evidence to date of the 
long-term benefit of LDCT compared to a shorter duration [15]. The likely explanation is that 
screening with LDCT works by identifying nodules that would have been diagnosed as LC several 
years later: the effect of screening therefore increases with repeated tests over a prolonged period. 
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3Replication of MILD results beyond five years of intervention and follow-up, either from NELSON [6] 
or from other studies, is essential to quantify the full effect of sustained LDCT screening on LC 
mortality and develop recommendations for long-term screening of high-risk individuals. 
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Table 1. Randomized trials of LDCT and lung cancer
Screening test & 
description
Participants
Median 
length of 
follow-up
Study Country LDCT Control
Age and sex 
of 
participants Smoking status LDCT Control
Pilot trials
LSS
Gohagan et al. 2005 [9]
Doroudi et al. 2018 [14]
US 2 annual 
LDCT
2 annual 
CXR
M & F 55-74 current ≥30 pack-
years, former quit 
<10 years
1600 1658 5.2 years
DEPISCAN
Blanchon et al. 2007 [10]
France Baseline 
LDCT
Usual 
care
M & F 50-75 current ≥15 
cigarettes/day, 
former quit <15 
years
330 291 Only 
baseline 
findings
UKLS
Field et al. 2016 [11]
UK Baseline 
LDCT
Usual 
care
M & F 50-75 5 years lung cancer 
risk ≥5% according 
to Liverpool Lung 
Project risk 
prediction model
2028 2027 Only 
baseline 
findings
Trials
NLST
Aberle et al. 2011 [2]
US 3 annual 
LDCT
3 annual 
CXR
M & F 55-74 current ≥30 pack-
years, former quit 
<15 years 
26722 26732 6.5 years
DANTE
Infante et al. 2015 [3]
Italy 4 annual 
LDCT
4 annual 
medical 
visits
M 60-74 current ≥20 pack-
years, former quit 
<10 years
1264 1186 8.4 years
LUSI
Becker et al. 2015 [12]
Germany 5 annual 
LDCT
Usual 
care
M & F 50-69 current ≥15 
cigarettes /day for 
>25 years or ≥10 
cigarettes/day for 
>30 years, former 
quit <10 years
2029 2023 ≈ 5 years
DLCST
Wille et al. 2016 [5]
Denmark 5 annual 
LDCT
5 annual 
medical 
visits
M & F 50-70 current ≥20 pack-
years, former quit 
<10 years
2052 2052 9.8 years
ITALUNG
Paci et al. 2017 [4]
Italy 4 annual 
LDCT
Usual 
care
M & F 55-69 current ≥20 pack-
years, former quit 
<10 years
1613 1593 9.3 years
AME
Yang et al. 2018 [13]
China Baseline 
LDCT
Usual 
care
M & F 45-70 current ≥20 pack-
years, former quit 
<15 years, family 
history of cancer, 
long history of 
passive smoking, 
occupational 
exposure
3512 3145 Only 
baseline 
results
NELSON
De Koning et al. 2018 [6]
Netherlands 
& Belgium
4 annual 
LDCT
Usual 
care
M & F 50-74 current ≥10 
cigarettes/day for 
>30 years or ≥15 
cigarettes/day for 
>25 years, former 
quit <10 years
7900 7892 > 10 years
MILD
Pastorino et al. 2019 [1]
Italy 7 annual 
LDCT / 4 
biennial 
LDCT
Usual 
care
M & F 49-75 current ≥20 pack-
years, former quit 
<10 years
2376 1723 > 10 years
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 Figure 1. Forest plot of lung cancer mortality in LDCT trials 
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